AzTrials
AzTrials

SmokingPSPNCT04282694

PRogetto Salute Parma

An observational study of Smoking and Smoking Habit, run by University of Parma at 1 site in Italy.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This project from the University Hospital of Parma (AOUPR) aims to verify the feasibility of a prevention program in our district, relying on advanced technological resources and highly experienced team in lung cancer early diagnosis, in order to identify useful elements towards the applicability of such a prevention… Read more about this study

Who is it for?
Ages 50 to 74 yearsHealthy volunteers can take part
Conditions the study is for
Smoking, Smoking Habit, Smoking, Tobacco
What is being tested?
Low-dose computed tomography (LDCT)
How many people
9 participants
Where
1 siteItaly
Study dates
12 Feb 2020to 30 Oct 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 74 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: We expect to recruit around 500 people in 1 year. This sample size is considered adequate based on the available resources, both human and economic.

Who may be able to join

  • Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years
  • Status of current smoker or ex-smoker for <10 years.

Who cannot join

  • Personal history of cancer within the prior 5 years

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • University of Parma

    Parma

Other trials in Italy

About this study

Official title: PRogetto Salute Parma: PRevenzione Primaria e Secondaria Del Danno da Fumo

This project from the University Hospital of Parma (AOUPR) aims to verify the feasibility of a prevention program in our district, relying on advanced technological resources and highly experienced team in lung cancer early diagnosis, in order to identify useful elements towards the applicability of such a prevention program on a large scale (regional, national).

Uncontrolled, monocentric experimental study with dynamic enrollment and prospective data collection, aimed at implementing a prevention program based on scientific evidence. This study is set to verify the applicability and feasibility of a lung cancer prevention program in a real context, including a preliminary evaluation at the smoking cessation clinic and a LDCT assessment with subsequent LDCT follow-up for participants who show indeterminate findings at the first LDCT (LDCT baseline) exam.

Read more

The main objective of the study is to verify the feasibility of a lung cancer prevention program according to internationally validated scientific methods.

Secondary objectives:

  1. To evaluate the use of local smoking cessation clinics and their effects in terms of smoking cessation (primary prevention)
  2. To evaluate the outcomes of the program in terms of number of patients with early (presymptomatic) lung cancer treated with minimally invasive surgery (secondary prevention)
  3. To evaluate the number of false positives and their diagnostic work-up (PET-CT, CT-guided biopsy, bronchoscopy)

Primary endpoint:

  • Percentage of enrolled subjects to whom the program was offered within 60 days from the date of enrolment and percentage of those who stop smoking for at least 12 months

Secondary endpoints:

  • To describe the organizational model, human resources employed, difficulties encountered and elements that have favoured its realization
  • To measure the variation in smoking habits in enrolled smokers
  • To describe the effect of annual LDCT on lung cancer diagnosis rates, considering size, shape, histology and site
  • To measure the consequent demand for further diagnostic investigations and treatment
  • To measure the number of false positives

Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program.

Inclusion criteria

  • Age between 50 and 75 years
  • Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years
  • Status of current smoker or ex-smoker for <10 years.

Exclusion criteria

  • Personal history of cancer within the prior 5 years

We expect to recruit around 500 people in 1 year. This sample size is considered adequate based on the available resources, both human and economic.

After closing and adjusting the database and before data analysis, a document called Statistical Analysis Plan (SAP) will be drawn up. It will consist of the following paragraphs:

  • Statistical methods planned in the study protocol;
  • Size of the sample;
  • Management of missing data;
  • Evaluation of the endpoints;
  • Statistical models that will be applied in the analysis. The socio-demographic characteristics of the enrolled subjects, the adopted organizational methods and the effects of the prevention program (endpoints) will be analyzed and described using tables and figures.

The project "PRogetto Salute Parma: Primary and secondary prevention of smoking-related lung cancer" will be started once approved by the institutional Ethics Committee and authorized by the General Manager. The study is expected to be carried out over 2 years (from the inclusion of the first subject), with an expected period of 1 year for the enrolment and 1 further year for follow-up.

Being tested
Low-dose computed tomography (LDCT)
Medical subject headings
Smoking, Tobacco Smoking, Cigarette Smoking, Smoking Cessation, Lung Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Low-dose computed tomography (LDCT)Diagnostic test

    Also called Smoking cessation

    Early detection of lung cancer by LDCT and smoking cessation counselling

Study groups in NCT04282694
Study groupRoleWhat they receive
High risk (former) smokersSubjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program. Inclusion criteria * Age between 50 and 75 years * Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years * Status of current smoker or ex-smoker for <10 years. Exclusion criteria • Personal history of cancer within the prior 5 years
Receives: Diagnostic Test: Low-dose computed tomography (LDCT)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Adherence

    Percentage of enrolled subjects to whom the program was offered within 60 days from the date of enrolment and percentage of those who stop smoking for at least 12 months

    Measured: 12 months

Secondary outcomes (5)
  1. Organization model

    To describe the organizational model, human resources employed, difficulties encountered and elements that have favoured its realization

    Measured: 18 months

  2. Smoking cessation

    To measure the variation in smoking habits in enrolled smokers.

    Measured: 24 months

  3. Secondary prevention of lung cancer

    To describe the effect of annual LDCT on lung cancer diagnosis rates, considering size, shape, histology and site.

    Measured: 24 mesi

  4. Work up burden

    To measure the demand for further diagnostic investigations and treatment generated by LDCT.

    Measured: 24 months

  5. False positives

    To measure the number of false positives generated by LDCT

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Feb 2020
  2. Study start12 Feb 2020
  3. Primary completion30 Oct 2020
  4. Study completion30 Oct 2020

Why it stopped: The worldwide surge of SARS-CoV-2 started during the first week of the study. The Investigators attempted to re-organize the project with a new agenda, but the time frame from the funding Organization did not comply with the study needs.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
9 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04282694
Sponsor's protocol ID
837/2019/OSS/UNIPR
Acronym
PSP
Status last verified
Feb 2020
First submitted
20 Feb 2020
Last updated
19 Nov 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Smoking and Smoking Habit, run by University of Parma at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 19 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: The worldwide surge of SARS-CoV-2 started during the first week of the study. The Investigators attempted to re-organize the project with a new agenda, but the time frame from the funding Organization did not comply with the study needs.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Adherence (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
PRogetto Salute Parma (NCT04282694) | AzTrials